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The activation of endothelial cells (ECs) is a crucial step on the road map of tumor
angiogenesis and expanding evidence indicates that a pro-oxidant tumor
microenvironment, conditioned by cancer metabolic rewiring, is a relevant controller of
this process. Herein, we investigated the contribution of oxidative stress-induced
ferroptosis to ECs activation. Moreover, we also addressed the anti-angiogenic effect of
Propranolol. We observed that a ferroptosis-like mechanism, induced by xCT inhibition
with Erastin, at a non-lethal level, promoted features of ECs activation, such as
proliferation, migration and vessel-like structures formation, concomitantly with the
depletion of reduced glutathione (GSH) and increased levels of oxidative stress and
lipid peroxides. Additionally, this ferroptosis-like mechanism promoted vascular
endothelial cadherin (VE-cadherin) junctional gaps and potentiated cancer cell adhesion
to ECs and transendothelial migration. Propranolol was able to revert Erastin-dependent
activation of ECs and increased levels of hydrogen sulfide (H2S) underlie the mechanism of
action of Propranolol. Furthermore, we tested a dual-effect therapy by promoting ECs
stability with Propranolol and boosting oxidative stress to induce cancer cell death with a
nanoformulation comprising selenium-containing chrysin (SeChry) encapsulated in a
fourth generation polyurea dendrimer (SeChry@PUREG4). Our data showed that novel
developments in cancer treatment may rely on multi-targeting strategies focusing on
nanoformulations for a safer induction of cancer cell death, taking advantage of tumor
vasculature stabilization.
Keywords: angiogenesis, ferroptosis, oxidative stress, lipid peroxidation, endothelial cell hyperactivation,
propranolol, polyurea dendrimers, tumor vasculature stabilizersMay 2021 | Volume 11 | Article 6562291
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Tumor blood vessels are essential to provide nutrients and
oxygen to cancer cells and for the elimination of waste
products. Besides the promotion of tumor growth, the
neovasculature acts as a gatekeeper for tumor cell invasion and
metastasis (1). In an ideal scenario, the tackling of tumor
angiogenesis would be an efficient anti-cancer approach, yet, so
far, the anti-angiogenic therapies have shown a lack of efficacy
and drug resistance (2, 3).
During angiogenesis, the balance between pro-angiogenic
factors (e.g., vascular endothelial growth factor - VEGF,
fibroblast growth factors - FGFs, and angiopoietins - ANGPTs)
and anti-angiogenic factors (e.g., endostatin, thrombospondin,
and angiostatin) plays a vital role in the regulation of the
angiogenic switch, a process characterized by the activation of
the quiescent endothelial cells (ECs) to form new blood vessels
(4). However, contrarily to physiological angiogenesis, cancer
neovessels are unorganized and leakier, suggesting that an
imbalance in pro- and anti-angiogenic factors or the activation
of unknown signaling pathways triggers a hyperactivation of the
angiogenic switch and further unstable cancer neovessel
formation (5).
Still, for both physiological and pathological angiogenesis the
oxidative stress represents a pro-angiogenic stimulus (6, 7).
Cancer neoangiogenesis seems to be more responsive to
oxidative stress than physiological angiogenesis because the
metabolic remodeling of malignant cells and tumor-associated
stromal cells contributes to the generation of a pro-oxidative
tumor microenvironment (8). At a molecular level, reactive
oxygen species (ROS) inhibit PHDs (prolyl hydroxylases)
leading to hypoxia-inducible factor 1a (HIF1a) stabilization,
and consequently to the transcription of VEGF and other pro-
angiogenic factors (6, 7).
The oxidative stress-dependent generation of lipid peroxides
underlies ferroptosis, a recently discovered process of
programmed cell death. In this process, iron ions (Fe2+)
promote lipid oxidation in a Fenton-like reaction, increasing
ROS levels alongside with intracellular glutathione (GSH)
depletion, leading to the impairment of the activity of
glutathione peroxidase 4 (GPX4), a GSH-dependent
hydroperoxidase responsible for the scavenging of lipid
peroxides (9, 10). The ROS-induced lipid peroxidation
damages membranar phospholipids directly and can also act as
cell death signal. Recent observations have shown that
ferroptosis is not strictly a cell death type; it can also be
as soc ia t ed wi th the regu la t ion of b io log i ca l and
pathophysiological processes, including carcinogenesis (9, 11).
Ferroptosis can be induced by angiopoietin-like 4 (ANGPTL4), a
potent angiogenic mediator that activates the TAZ-ANGPTL4-
NOX2 (transcriptional coactivator with PDZ-binding motif-
ANGPTL4-NADPH oxidase 2) axis. This axis is responsible
for the activation of NADPH oxidase 2 (NOX2), that induces
the superoxide radical generation, which in turn acts as an
activator of ferroptosis (12), suggesting a correlation between
ferroptosis and angiogenesis induction.Frontiers in Oncology | www.frontiersin.org 2In the last years, Propranolol, a liposoluble non-selective b-
blocker, without an intrinsic activity (13) and with a well-known
membrane stabilizing effect (14), firstly indicated as an anti-
hypertensive drug was repurposed as a first-line therapy
for vascular tumors, such as infantile hemangiomas and
cavernomas (15, 16). Furthermore, breast cancer patients
exposed to b-blockers prior or after diagnosis had a better
disease prognosis and less metastases (17–19). So far, it is
recognized that the impairment of angiogenesis by Propranolol
involves the downregulation of VEGF and FGF expression, and
consequently the inhibition of mitogen-activated protein kinase
(MAPK) signaling pathway (20, 21). Although it seems to be
independent of its b-blocker action (22), the specific mechanism
(s) of action by which Propranolol affects ECs and angiogenesis
remains to be clarified. A paper from Sasaki’s team demonstrated
that Propranolol downregulates the expression of ANGPTL4 in
hemangioma cells (22). ANGPTL4 regulates angiogenesis in a
context-dependent manner, acting as a pro- or as an anti-
angiogenic factor (23, 24).
Apart from the inhibition of ANGPTL4 expression and
consequent abrogation of NOX2 activation, Propranolol could
also interfere with ferroptosis through the inhibition of
cytochrome P450 (CYP450) enzymes, whose activity promotes
ROS and lipid peroxidation (25, 26). Propranolol is a substrate of
CYP450s (27–29), acting as an inhibitor of CYP2D6 (30),
CYP2C19 (31) and CYP1A2 (27, 32) isoenzymes. Recently,
Mishima et al. identified the anti-ferroptotic properties of
Propranolol, which promoted lipid peroxyl radicals scavenging
in a b1 activity-independent manner (29). Although the
mechanism underlying the anti-angiogenic effect of
Propranolol is not clear, it was shown that it does not involve
apoptosis (33).
Here, we investigated if ECs activation needed for
angiogenesis might be triggered by a ferroptosis-like
mechanism. In addition, we disclosed if this mechanism
contributes to the anti-angiogenic effect of Propranolol. Finally,
we made a pilot proof of concept approach to address the
hypothesis that a promising chemotherapeutic strategy could
combine inducers of cell death and ECs stabilizers.MATERIAL AND METHODS
Cell Culture
Three different batches corresponding to three different-original
donors of Human umbilical vein endothelial cells (HUVECs:
CRL-1730, ATCC) were used. HUVECs were cultured in
Endothelial Cell Growth Basal Medium-2 (EBM-2: CC-3156,
Lonza, Bioscience) supplemented with EGM-2 SingleQuots
Supplements (CC-4176, Lonza, Bioscience). All experiments
were performed until the passage 10. Triple-negative breast
cancer (MDA-MB-231: HTB-26™, ATCC) were used as tumor
models, being cultured in Dulbecco’s Modified Eagles Medium
(DMEM) (41965-039, Gibco, Life Technologies), supplemented
with 10% fetal bovine serum (FBS) (S 0615, Merck), 1%May 2021 | Volume 11 | Article 656229
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µg/mL Gentamicin (15750-060, Gibco, Life Technologies). Cell
cultures were maintained at 37°C in a humidified environment of
5% CO2. Cells were detached with 0.05% Trypsin-EDTA 1 ×
(25300-054, Invitrogen, Thermo Fisher Scientific) at 37°C for
approximately 5 min and split to new plates according to the
experimental procedures.
Regarding experimental conditions, cells were cultured with
15 mM hydrogen peroxide (H2O2; 1.07210.0250, Merck), as a
ROS generator, 1.5 mM Erastin (E7781, Sigma) as a ferroptosis
inducer, 100 mM Propranolol (P8688, Sigma Aldrich) and 160
and 200 mM SeChry@PUREG4, for 6 and 16 h.
Cell Death Analysis by Flow Cytometry
To analyze the effects of Propranolol, Erastin and SeChry on cell
death, HUVECs (5×104 cells/well) and MDA-MB-231 (5×104
cells/well) were seeded in 24-well plates. After exposure to the
experimental conditions, supernatants and cells were collected
and centrifuged at 155 × g for 5 min. Cell pellets were incubated
with 0.5 mL FITC-labeled Annexin V (640906, BioLegend) in
Annexin V binding buffer 1× (10 mM Hepes (pH 7.4) (391333,
Millipore), 0.14 M sodium chloride (NaCl; 106404, Merck), 2.5
mM calcium chloride (CaCl2; 449709, Sigma Aldrich) and
incubated at room temperature for 15 min, in the dark. After
incubation, cells were rinsed in 200 mL PBS 1×/0.1% (v/w) bovine
serum albumin (BSA) and centrifuged at 155 × g for 2 min. The
remaining pellet was resuspended in 200 mL of annexin V
binding buffer 1× and 2.5 mL of 50 mg/mL propidium iodide
(PI; P4170, Sigma Aldrich Aldrich) and analyzed by flow
cytometry (FACScalibur – Becton Dickinson). FlowJo X v10.0.7
software (https://www.flowjo.com/) was used to analyze data.
Wound Healing Assay
Cells were plated in 24-well plates (1×105 cells/well) until the
formation of a confluent monolayer. Once confluent, cells were
incubated for 3 h with 5 mg/mL mitomycin-C (M4287, Sigma
Aldrich) and a linear scratch in each monolayer was made with a
P200 pipette tip, creating a wound across the well diameter. The
media was replaced to remove debris and cells in suspension and
the experimental conditions were added. Bright-field images of
each well were acquired on the Olympus IX53 Inverted
Microscope at the following timepoints: 0, 2, 4, 6, 8, 10 and
24 h. The wound closure was quantified using the ImageJ
software (imagej.nih.gov/ij/).
Tube-Forming Assay
A 48-well plate was coated with 100 µL matrigel (354230,
Corning) and incubated at 37°C for 30 min until solidification.
HUVECs were incubated with 2 mg/mL calcein (C1430,
Invitrogen), a fluorescent cell permeable dye, for 30 min at 37°C
and 5% CO2 and seeded (3×10
4 cells/well) on the top of matrigel.
Cells were exposed to the experimental conditions for 6h and
representative images of the formed tube-like structures were
acquired on an Olympus IX53 Inverted Microscope and
analyzed with ImageJ software (imagej.nih.gov/ij/). The density
of vessel-like structures formation (branch points number/mm2)
was calculated as representative of vascular density.Frontiers in Oncology | www.frontiersin.org 3Reactive Oxygen Species (ROS)
Quantification by Flow Cytometry
HUVECs (5×104 cells/well) and MDA-MB-231 cells (5×104
cells/well) were plated in 24-well plates. The intracellular ROS
were detected in cells incubated with 10 mM DCF-DA probe
(D6883, Sigma Aldrich) and mitochondrial ROS were detected in
cells incubated with 5 mM MitoSox Red probe (M36008,
Invitrogen), both at 37°C for 30 min. The acquisition was
performed with FACScalibur (Becton Dickinson) and data




HUVECs (5×104 cells/well) were plated in 24-well plates. After
experimental conditions, cells were incubated with 2 mM C11-
Bodipy 581/591 (D3861, Invitrogen), for 30 min at 37°C in the
dark. The excess dye was removed by washing with 2% FBS-1X
PBS and cell pellets were resuspended in 2% FBS-1× PBS for the
acquisition by flow cytometry (FACScalibur – Becton
Dickinson). FlowJo X v10.0.7 software (https://www.flowjo.
com/) was used to analyze data.
High-Performance Liquid
Chromatography (HPLC)
HUVECs were plated in 6-well plates (2×105 cells/well) and after
collection, cell pellets were lysed with 0.01% triton-PBS and
centrifuged at 20 000 g, for 10 min at 4 °C. The assessment of
pools of cysteine and GSH (total availability, total free fraction,
reduced free, protein bound and oxidized pools) of lysed cells
and supernatants was performed according to (34) and adapted
to cell culture. The cysteine (Cys) and glutathione (GSH)
metabolites were separated on a reversed-Phase C18
LiChroCART 250-4 column (LiChrospher 100 RP-18, 5 µm,
VWR, USA) on isocratic elution mode for 22 min, at a flow rate
of 0.6 mL/min by HPLC system (Shimadzu Scientific
Instruments Inc) with a fluorescence detector operating at
excitation and emission wavelengths of 385 and 515 nm,
respectively. The mobile phase consisted of 100 mM acetate
buffer (pH 4.5) and methanol (98:2 (v/v)). The concentrations of
these thiols were normalized to the protein assessed with
Bradford method (500-0006, Bio Rad). Results are presented
as: Total GSH: levels of free form of oxidized or reduced GSH and
GSH bound to proteins, it is the total pool of GSH in the cell;
Free-total GSH: levels of free form of oxidized or reduced GSH,
the total pool of GSH that is not bound to proteins; Free-reduced
GSH: levels of reduced GSH free in the cell, and GSSG: levels of
oxidized GSH free in the cell.
Reverse Transcription and Quantifying
PCR (RT-qPCR)
HUVECs (2×105 cells/well) were plated in 6-well plates and after
exposure to the experimental conditions, the RNA was extracted
using RNeasy Mini Extraction kit (74104, Qiagen) and the cDNA
synthesized from 1 µg RNA and reversely-transcribed by
SuperScript II Reverse Transcriptase (18080e44, Invitrogen),May 2021 | Volume 11 | Article 656229
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Real-Time PCR was performed using Power SYBR Green PCR
Master Mix (4367659, Applied Biosystems), according to
manufacturer’s protocol and carried out in a LightCycler 480
instrument (Roche). The transcriptional expression of genes
encoding prostaglandin-endoperoxide synthase 2 (PTGS2),
glutathione peroxidase 4 (GPX4) and glutathione synthetase
(GSS) was evaluated, using the primers: PTGS2 (Fwd: CTGG
CAGGGTTGCTGGTG; Rev: CATCTGCCTGCTCTGGTC);
GPX4 (Fwd: GCAGGAGCCAGGGAGTAAC; Rev: CCTTG
GGTTGGATCTTCATCC), and GSS (Fwd: GAGAGAGGGT
GGAGGTAAC; Rev: CCATGAGGATGTAGGAGGCC).
Hypoxanthine-guanine phosphoribosyltransferase (HPRT;
Fwd: TGACACTGGCAAAACAATGCA; Rev: GGTCCTTTTC
ACCAGCAAGCT) was used as housekeeping gene.
Quantification of H2S in Cell Homogenates
HUVECs (2×105 cells/well) were seeded in 6-well plates and
cultured under the experimental conditions, for 16 h. After, cells
were scrapped in PBS 1× and centrifuged at 210 × g for 5 min.
The cell pellet was homogenized in NP40 lysis buffer (1% NP40,
150 mM NaCl, 50 mM Tris-Cl, pH 8.0) on ice for 30 min and
centrifuged for 5 min at 20,000 × g 4°C. Cell homogenates (20
µL) were incubated in black 96-well plates with 80 µL of 10 µM 7-
Azido-4-Methylcoumarin probe (AzMC, L511455, Sigma
Aldrich). The protein concentration was determined with
Bradford method using protein assay dye reagent concentrate
(500-0006, Bio Rad). The H2S measurements were posteriorly
normalized to the total protein concentration and to a blank
sample (cellular lysates without probe). H2S production was
monitored following fluorescent signal of AzMC probe (355
nm/460 nm) every 30 min for 2 h, in a VIKTOR3 instrument
from PerkinElmer/Wallac 1420 v3.0 software.
Immunofluorescence
For Ki67, ICAM and VCAM immunodetection, HUVECs
(5×104 cells/well) were cultured on glass slides with 0.2%
gelatin coating and fixed in 2% paraformaldehyde, for 15 min
at 4°C. After blocking with 1% BSA-1× PBS, cells were incubated
with primary antibodies (anti-Ki67, 1:100 in 1% BSA-0.1% triton
X-100- 1× PBS (w/v/v); sc-15402, Santa Cruz; anti-ICAM and
anti-VCAM, 1:500 in 0.1% BSA-0.1% triton X-100-PBS (w/v/v);
SRC023, Millipore), overnight at 4°C, followed by an incubation
with secondary antibodies (Alexa Fluor 488 goat anti-rabbit,
1:1000 in 1% BSA-0.1% triton X-100-PBS; A-11078, Invitrogen -
Thermo Fisher Scientific; Alexa Fluor 488 goat anti-mouse;115-
545-003, Thermo Fisher Scientific and Alexa Fluor 594 donkey
anti-mouse; A21203, Thermo Fisher Scientific both at 1:1000 in
0.1% BSA-0.1% triton X-100-PBS), for 2 h at room temperature.
For the cystine/glutamate antiporter system xc- (xCT)
immunodetection, after fixation cell were incubated with 50
mM ammonium chloride (NH4Cl) for 10 min, followed by
blocking and incubation with anti-xCT (1:100 in 0.5% BSA-
0.1% saponin-PBS (w/v/v); ab1756, Millipore), for 30 min at
room temperature.
For VE-Cadherin (VE-Cad) immunodetection, HUVECs
(1×105 cells/well) were cultured in 24-well plate with glassFrontiers in Oncology | www.frontiersin.org 4slides coated with 0.2% gelatin, until the formation of a
confluent monolayer. After fixation and blocking, cells were
incubated anti-VE-Cad (1:50 in 3% BSA-0.1% triton X-100-
PBS (w/v/v); AF938, R&D), for 2 h at room temperature,
followed by an incubation with the secondary antibody (Alexa
Fluor 488 donkey anti-goat, 1:500 in 3% BSA-0.1% triton X-100-
PBS; A11055, Thermo Fisher Scientific), for 2 h at
room temperature.
All slides were mounted in VECTASHIELDmedia with DAPI
(4′-6-diamidino-2-phenylindole; H-1200, Vector Labs) and
examined by standard fluorescence microscopy, using an Axio
Imager.Z1 microscope (Zeiss) with a CytoVision® software.
The determination of cell proliferation rate was based on the
ratio of total and Ki67+ nuclei and the quantification of ICAM and
VCAM expression per cell was calculated according to the formula
CTCF (corrected total cell fluorescence) = integrated density – (area
of selected cell × mean fluorescence of background reading), both
using ImageJ software (imagej.nih.gov/ij/).
Cancer Cells Endothelial Adhesion
In a 24-well plate, calcein labelled-MDA-MB-231 (5×104 cells/
well) were seeded on the top of a HUVECs (1×105 cells/well)
monolayer pretreated with 100 ng/mL TNFa (H8916, Sigma),
for 24 h. MDA-MB-231 were incubated with HUVECs (exposed
previously to TNFa and experimental conditions) for 40 min, at
37°C in a humidified environment of 5% CO2. The non-adherent
cells were removed by washing with PBS1X and images were
acquired on an Olympus IX53 Inverted Microscope and analyzed
using ImageJ software (imagej.nih.gov/ij/). Three fields in each
well were evaluated (10× magnification).
Transendothelial Cancer Cells Migration
HUVECs (5×104 cells/well) were plated in 8µm pore transwells
(upper wells) (3422, Corning) and exposed to 100 ng/mL TNFa
for 24 h, and to experimental conditions for 16 h. MDA-MB-231
previously plated under starvation using serum-free DMEM, for
24 h, were incubated with calcein (2 mg/mL) and seeded (1.5×104
cells/well) in serum free DMEM on the top of the HUVECs
monolayer, for 5 h. Complete media was added to the lower well
and used as chemoattractant. Cells on the upper Transwell®
surface were removed with a cotton swab and the invading
MDA-MB-231- calcein labeled cells were photographed on an
Olympus IX53 Inverted Microscope. Three fields in each well




Monocytes isolation from peripheral blood of healthy blood
donors (IPOLFG-Ethical committee UIC-1137) and further cell
characterization was performed as described by Lopes-Coelho
et al. (35). Briefly, monocytes cultured for 4 days in colony-
forming unit (CFU) medium (130-091-277, MACS Technology)
and for 1 day in complete EBM-2 were incubated with von
Willebrand factor (vWF; 1:500 in 0.5% BSA-0.1% saponin-PBS;
A0082, Dako), for 60 min at 4°C with gentle shaking, followed by
the incubation with Alexa Fluor 488 anti-rabbit, for 30 min at 4°May 2021 | Volume 11 | Article 656229
Lopes-Coelho et al. Oxidative Stress Potentiates Endothelial ActivationC in the dark, with gentle shaking. H2O2 (15 mM) was used as a
promoter of monocytes differentiation into ECs (35). vWF
expression was detected by flow cytometry in a FACScalibur–
Becton and data were analyzed using the FlowJo X v10.0.7
software (https://www.flowjo.com/).
SeChry@PUREG4 Synthesis
Selenium-containing chrysin (SeChry) was synthesized
following a reported protocol (36). After purification, the
formation of the product was confirmed by 1H NMR. 1H
NMR (CDCl3, 400 MHz) d (ppm): 7.96 (2H, d, J= 8.0 Hz),
7.76 (1H, s), 7.61 (1H, t, J= 8.0 Hz), 7.52 (2H, t, J= 8.0 Hz), 6.51
(1H, d, J= 4.0 Hz), 6.46 (1H, d, J= 4.0 Hz). Polyurea dendrimer
generation four (PUREG4) was obtained using our
supercritical-assisted polymerization protocol (37). SeChry
was encapsulated in PUREG4 nanoparticles following our
protocol (38). Briefly, SeChry (6.5 mg) was added to an
aqueous solution (10 mL) of PUREG4 (125 mg) and stirred
overnight. Then, the aqueous solution was extracted with
CHCl3 to remove non-encapsulated or surface bound
SeChry. No SeChry was found in the CHCl3 extracts (control
by thin layer chromatography, TLC), thus confirming a full
encapsulation. The release profile follows the usual profile
reported for this nanodelivery system (39, 40).
Statistical Analysis
All data were analyzed using student’s t-test, one-way ANOVA
or two-way ANOVA in GraphPad Prism v7 software (www.
graphpad.com/). The assays were performed with at least 3
biological replicates per condition and the differences were
determined statistically significant at p value < 0.05.RESULTS
A Ferroptosis-Like Mechanism Induced
by Erastin Promotes ECs Activation,
Which Is Impaired by Propranolol
Through the Increase of H2S Levels
Erastin was used as a ferroptosis activator since it inhibits xCT
(encoded by SLC7A11), which is responsible for the import of
cystine (41, 42), the main source of cysteine to sustain GSH
synthesis (43) . xCT inhibit ion, impairs GPX4 and
consequently leads to an increase in lipid peroxidation
that is mediated by free active iron (44), and further
ferroptosis (45).
After confirming the expression of xCT in HUVECs (Figure
S1A) and upon Erastin administration the ferroptosis-related
features were analyzed. HUVECs exposed to Erastin presented
an increase in intracellular levels of ROS (Figure 1A) and lipid
peroxide levels (Figure 1C), without affecting mitochondrial
ROS (Figure 1B) but decreasing the GSH levels (Figure 1D).
Moreover, the inhibitory effect of Erastin in cyst(e)ine uptake
was confirmed, since cells exposed to Erastin presented high
levels of total cysteine (free oxidized+free reduced+protein
bound) in culture medium (Figure 1E). Interestingly, afterFrontiers in Oncology | www.frontiersin.org 5Erastin exposure the increased generation of ROS (Figure 1A)
and lipid peroxides (Figure 1C), the depletion of GSH (Figure
1D) and the downregulation of genes involved in the scavenging
of lipid peroxides (Figures 1F, G) and GSH synthesis (Figure
1H), did not promote ferroptosis-induced ECs death (Figure 1I).
Moreover, we observed that Propranolol decreased intracellular
ROS levels (Figure 1A) and also reverted the levels of ROS
(Figure 1A) and lipid peroxides induced by Erastin (Figure 1C).
Accordingly, Propranolol, alone or in combination with Erastin,
decreased the levels of free (oxidized + reduced) and total GSH,
maintaining the oxidized GSH levels similar to the control
condition (Figure 1D).
Since GSH levels were not increased, we hypothesized that
hydrogen sulfide (H2S) generation might underlie the
antioxidant properties of Propranolol. H2S, a product of
cysteine degradation (46, 47), is a powerful antioxidant (48)
with a reduction potential similar to the couple glutathione
disulfide/glutathione (GSSG/GSH) (49). There was an increase
in H2S production upon Propranolol administration, while
Erastin did not affect H2S levels (Figure 1J). This suggests that
Propranolol favors cysteine flux for catabolism and not for GSH
synthesis. Moreover, when Propranolol was combined with
Erastin, the levels of H2S were similar to the control condition.
Together, these results suggest that Propranolol’s antioxidant
effect is mediated by H2S.
Afterwards, we investigated if the generation of ROS-induced
lipid peroxides promoted ECs activation, through this
ferroptosis-like mechanism. It was observed that Erastin
exposure increased HUVECs proliferation (Figure 2A) and
migration (Figure 2B), suggesting that the ferroptosis-like
mechanism has a role in the promotion of ECs activation,
without affecting cell viability (Figure 1I).
Considering that Propranolol acts as an inhibitor of
angiogenesis and ferroptosis, its interference with ferroptosis-
mediated angiogenesis was also evaluated. In fact, HUVECs
exposed to Propranolol showed decreased proliferation (Figure
2A) and migration (Figure 2B) and increased cell death, at 16h
(Figure 1I). Moreover, Propranolol was able to revert the Erastin
effect at 16h, leading to the inhibition of HUVECs proliferation
(Figure 2A) and migration (Figure 2B), as well as disturbing cell
viability (Figure 1I).
Since the pro-oxidative microenvironment promotes
angiogenesis (6, 7), the HUVECs capacity to form vessels-like
structures was tested under oxidative conditions, in an in vitro
tube-forming assay, upon H2O2 exposure. Erastin exposure
increased the branch points density at the same range of H2O2,
and no cumulative effects between Erastin and H2O2 were
observed (Figure 2C). Moreover, Propranolol decreased the
vessel-like structure formation (Figure 2C) and reverted the
stimulation by H2O2 and Erastin (Figure 2C). This effect of
Propranolol was observed even when Propranolol was added to
the vessel-like structures already formed in the presence of
Erastin (Figure 2D). These results indicate that the
Propranolol anti-angiogenic effect is related, at least in part, to
the abrogation of the ferroptosis-like mechanism induced
by Erastin.May 2021 | Volume 11 | Article 656229








FIGURE 1 | Erastin (Era) promotes increased levels of ROS-induced lipid peroxides and Propranolol (Prop), through the generation of hydrogen sulfide (H2S),
is able to revert it. (A) The levels of intracellular ROS (DCF-DA) decrease upon Prop exposure, and Era, although increasing the ROS levels, when co-
administrated with Prop the levels are similar to the control, at 6 and 16h. (B) The levels of mitochondrial ROS, assessed by MitoSox, are not affected by the
presence of Era and/or Prop, at 6 and 16h. (C) Era induces lipid peroxides (C11-Bodipy) generation and although Prop alone did not affect the lipid
peroxides content, its combination with Era reverts the levels generated by Era, being this effect more prominent at 16h. (D) The levels of GSH (total and LT:
free total) decrease upon exposure to Era and/or Prop for 16h. (E) The variation of the extracellular levels of cysteine (Cys) indicate that Era inhibits the
uptake of Cys by HUVECs, while Prop does not interfere with this process. (F–H) Show the regulation of transcriptional expression of genes encoding,
respectively, prostaglandin-endoperoxide synthase 2 (PTGS2), glutathione peroxidase 4 (GPX4) and glutathione synthetase (GSS). Erastin decreases
significantly GPX4 and PTGS2 expression and tend to decrease GSS expression, being this effect rescued by propranolol. (I) Era does not affect HUVECs
death (annexin V plus PI positive cells) while 16h of Prop exposure, with and without Era, increases the ratio of HUVECs death. (J) Era does not affect H2S
levels of HUVECs while Prop increases, at 16h. In graphs the dashed line represents the control condition. All data are normalized to the control condition
and represented as mean ± SD. *p<0.5, **p<0.01, ***p<0.001, ****p<0.0001.Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6562296




FIGURE 2 | The ferroptosis-like mechanism driven by Erastin (Era) promotes endothelial cell (ECs) activation and Propranolol (Prop) impairs the phenotype
induced by Era exposure. (A) The ferroptosis-like mechanism, generated by Era exposure, promotes HUVECs proliferation (increased ratio of Ki67+ (green)
nuclei/total nuclei), while Prop decreases the rate of HUVECs proliferation and impairs the phenotype induced by Era. The panel shows representative
microscope images of the Ki67 staining. (B) Era fosters HUVECs migration (increased % wound closure) and Prop inhibits and reverts the phenotype
induced by Era. (C, D) Era increases the branch point density of vessel-like structures (proxy for vascular density) at the same range of H2O2 (ROS; positive
control), with no additive effect. Prop, besides the impairment of vessel-like structures formation (decreased branch point density), inhibits the phenotype
induced by Era, even when Prop is added to the vessel-like structures already formed in the presence of Era (Era+Prop (2h)) and contrariwise (Prop+Era
(2h)). In graphs the dashed line represents the control condition. All data are normalized to the control condition and represented as mean ± SD. **p<0.01,
***p<0.001, ****p<0.0001.Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6562297
Lopes-Coelho et al. Oxidative Stress Potentiates Endothelial ActivationA Ferroptosis-Like Mechanism Induced by
Erastin Promotes the Generation of
Leakier ECs Structures Which Are
Normalized by Propranolol, Blocking
Cancer Cell Adhesion and
Transendothelial Migration
The generation of a pro-oxidative microenvironment is
correlated with the formation of disorganized and leakier
vessel networks (5). Thus, the adhesion structures in HUVECs
were evaluated, through VE-Cad immunodetection. VE-Cad is a
component of ECs adherents junctions, crucial for the stability
and function of the mature vessels (50). Erastin affected the
HUVECs monolayer stability, by increasing VE-Cad intercellular
junctional gaps, and Propranolol reverted this effect (Figures 3A,
B). This indicates that the proliferation of ECs is mediated by a
ferroptosis like-mechanism (Figure 2A), although they form
more instable structures due to increased intercellular
junctional gaps between ECs (Figures 3A, B). Interestingly,
Propranolol reverted this phenotype (Figures 3A, B), inducing
the stabilization of the ECs monolayer.
ICAM and VCAM adhesion molecules are important for
cancer cell-EC interaction during the metastatic cascade (51–
53), thus, we evaluated their expression. HUVECs exposed to
Erastin significantly increased ICAM expression, as well as
VCAM expression, although not in a statistically significant
level (Figures 3C–E). On the contrary, Propranolol alone did
not alter ICAM and VCAM expression, but it reverted the
effect of Erastin by decreasing ICAM and VCAM levels
(Figures 3C–E).
Considering the increased expression of ICAM (Figures
3C, D), we have also explored the effect of Erastin and
Propranolol in the adhesion of cancer cells to ECs and in
transendothelial migration. The triple negative breast cancer
cell line MDA-MB-231 was co-cultured on the top of a
previously established HUVECs monolayer exposed to
Erastin and/or Propranolol. Erastin increased the number of
cancer cells adherent to the ECs monolayer and stimulated
transendothelial migration, while Propranolol reverted both
Erastin effects (Figures 3F, G). Our results indicate that a
ferroptosis-like mechanism has also a role in the promotion of
vessel permeability and in cancer cell adhesion and
extravasation. Summing up, Propranolol was able to revert
the phenotype induced by Erastin, decreasing the intercellular
junctional gaps (Figures 3A, B), the cancer cell adhesion to
ECs (Figure 3F) and transendothelial migration (Figure 3G),
therefore suggesting that Propranolol could eventually impair,
or at least retard, the metastatic process (17).Neither Erastin nor Propranolol Affect
Monocytes (EPCs) Differentiation in ECs
Recently our group disclosed that monocytes act as endothelial
progenitor cells and their differentiation into ECs and
incorporation in blood vessels depend on a ROS-enriched
microenvironment (35). Considering the effect of a ferroptosis-Frontiers in Oncology | www.frontiersin.org 8like mechanism in ECs activation, we explored its impact on the
differentiation route of monocytes into ECs, assessed by the gain
of von Willebrand factor (vWF). Erastin and/or Propranolol
exposure had no effect in vWF expression and their concomitant
exposure with a H2O2 stimulation (positive control of the
differentiation pattern of monocytes) did not affect the vWF
expression stimulated by H2O2 (Figure 4A). Moreover, ROS and
lipid peroxide (Figures 4B, C) levels did not alter with Erastin
exposure after H2O2 stimulation. In contrast to ECs, Propranolol
did not affect ROS and lipid peroxide levels in monocytes
(Figures 4B, C), suggesting that the antioxidant role of
Propranolol verified during ECs activation did not interfere
with the differentiation process of monocytes towards ECs.
Sechry@PUREG4 Plus Propranolol:
A Putative Anti-Cancer Strategy, Acting
on Both Cancer Cell Death and ECs
Hyperactivation Prevention
The anti-angiogenic therapy to treat cancer has an efficiency far
from the expected. Thus, a promising therapeutic approach
would be a dual-effect therapy, which is cytotoxic to cancer
cells and stabilizes the vessels, in order to improve the delivery of
chemotherapy to the tumor.
Recently, our team showed that SeChry@PUREG4
nanoformulation had an anti-tumoral effect thereby depleting
GSH and inhibiting the H2S producing enzyme, cystathionine
beta synthase (CBS) (38). Thus, SeChry@PUREG4 is a good
candidate to be tested with Propranolol, in a dual-effect therapy,
inducing cancer cell death and stabilizing tumor vessels. Hence, we
investigated the SeChry@PUREG4 effect with and without
Propranolol on MDA-MB-231 and HUVECs. Interestingly,
MDA-MB-231 were more sensitive to Propranolol exposure than
ECs (Figures 5A and 1I), increasing MDA-MB-231 cell death by 2-
fold (Figure 5A). The two tested concentrations of SeChry@
PUREG4 (160 and 200 mM) promoted cancer cell death, mainly
when combined with Propranolol (Figure 5B). Interestingly,
HUVECs cell death was not altered by 160 mM SeChry@PUREG4
and a slight increase was observed with 200 mM SeChry@PUREG4
(Figure 5B). These results confirmed the anti-tumoral function of
SeChry and indicate that Propranolol has distinct effects on the
viability of cancer cells and ECs.
Regarding the effect SeChry@PUREG4 exposure on the
intracellular ROS levels, while in cancer cells the combination
of SeChry@PUREG4 and Propranolol induced an additive
increase in ROS levels, in HUVECs the addition of
Propranolol had the opposite effect, reinforcing the previously
observed antioxidant role of Propranolol in ECs (Figures 5C, D).
Accordingly, the ROS-induced lipid peroxide levels increased
upon SeChry@PUREG4 with or without Propranolol exposure, in
MDA-MB-231 (Figure 5E) but not in HUVECs (Figure 5F).
Moreover, HUVECs exposed to SeChry@PUREG4 presented a
more stable monolayer with reduced VE-Cad intercellular
junctional gaps (Figure 5G).
Together, these results suggest that SeChry@PUREG4 plus
Propranolol could be an interesting strategy for cancerMay 2021 | Volume 11 | Article 656229
Lopes-Coelho et al. Oxidative Stress Potentiates Endothelial Activationtreatment, targeting both cancer cells and ECs. In cancer cells,
SeChry@PUREG4 and Propranolol would have anti-tumor effects
through the promotion of cell death mediated by ferroptosis,
whereas in ECs, Propranolol would impair oxidative stress-
induced mechanisms, blunting ECs hyperactivation and
promoting stabil i ty , which in turn might decrease
transendothelial cancer cell migration and impair metastasis.Frontiers in Oncology | www.frontiersin.org 9DISCUSSION
During tumorigenesis, the increased metabolic rate of cancer cells
drives the generation of a pro-oxidative tumor microenvironment,
responsible for the production and release of pro-angiogenic factors
by cancer and tumor-associated stromal cells (54, 55). The ROS







FIGURE 3 | Erastin (Era) promotes the generation of a leakier EC monolayer while increases cancer cell-EC interaction and transendothelial migration. (A) The
ferroptosis-like mechanism driven by Era promotes an increased generation of intercellular VE-Cadherin (VE-Cad) gaps per 100µm2, while Propranolol (Prop) is able
to revert this phenotype. The panel shows representative images (scale: 10 µm) of VE-Cadherin (green) intercellular junctional gaps (arrows) in HUVECs exposed to
Era and/or Prop for 16h. (B) Quantification of VE-Cad junctional gaps. (C) Immunofluorescence for ICAM and VCAM detection. (D) ICAM intensity per cell (HUVECs;
A.U.: arbitrary units) increases upon Era exposure and although Prop alone does not affect ICAM expression, it is able to abrogate the expression induced by Era, at
16h. (E) VCAM intensity per cell (A.U.: arbitrary units) shows a tendency to increase under Era exposure. The ferroptosis-like mechanism, induced by Era, promotes
cancer cell (MDA-MB-231-calcein labelled cells) adhesion to HUVECs (F) and transendothelial migration (G). Prop alone has no effect but impairs cancer cell
adhesion and transendothelial migration induced by Era. The panels show representative microscope images (scale: 100 µm; MDA-MB-231-calcein labelled cells
(green)). All data are normalized to the control condition and represented as mean ± SD. *p<0.05, **p<0.01, ***p<0.001.May 2021 | Volume 11 | Article 656229
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The major production of ROS depends on NOX, which generate
O2.
- through the transfer of electrons from NADPH to oxygen (56–
59). The generation of NOX-dependent ROS increases VEGF
secretion and angiogenesis, in a HIF1a-dependent manner (60).
Therefore, the generation of a pro-oxidative and pro-angiogenic
tumor microenvironment seems to work synergistically in the
promotion of tumor angiogenesis.
Ferroptosis has been firstly described as an iron-dependent
programed cell death characterized by the accumulation of lipid
peroxides (61), although new evidences have shown that
ferroptosis is not a strict cell death mechanism, being relevant in
the regulation of biological and pathophysiological processes (9–
11, 62–64). Ferroptosis-inducing compounds, as Erastin, affect the
antioxidant capacity of cells through the inhibition of xCT, also
expressed in ECs (HUVECs) (Figure S1A). The impairment of
xCT activity disturbs cystine import, the main source of cysteine
for GSH synthesis. GSH acts as an electron donor to reduce lipid
hydroperoxides upon GPX4 action (9, 10, 65). Besides the role of
GSH as a scavenger, the proteins S-glutathionylation should be
explored in the future, since it seems to be a mechanism of redox
switch in ECs accounting for vascular homeostasis (66). So far,
there are no specific markers of ferroptosis as a cell death
mechanism and because we were exploring the non-lethal effectFrontiers in Oncology | www.frontiersin.org 10of ferroptosis, in this work we evaluated the levels of ROS-induced
lipids peroxides underlying ferroptosis and GSH dynamics (67).
The expression of genes pointed as being decreased upon
ferroptosis activation, PTGS2, GPX4 and GSS was also assessed
(10, 68–70). In our experimental conditions, we observed that
Erastin significantly decreases cyst(e)ine uptake (Figure 1E) and
promotes the increase of intracellular ROS (Figure 1A) and lipid
peroxide levels (Figure 1C), without affecting the mitochondrial
ROS content (Figure 1B). In agreement, the GSH depletion
(Figure 1D) and the decreased expression of PTGS2, GPX4 and
GSS genes (Figures 1F–H) was observed upon Erastin exposure.
All these ferroptosis-like features did not account for ECs death
(Figure 1I).
The anti-ferroptotic property of Propranolol has been recently
described, showing that the peroxyl radicals scavenging property is
independent of b1-blockade activity (29). Here, we observed that
Propranolol decreased reduced and total GSH levels, but it kept the
GSSG (oxidized GSH) levels similar to control conditions (Figure
1D), as well as it decreased the intracellular ROS levels (Figure 1A)
and reverted the accumulation of ROS-induced lipid peroxides
induced by Erastin (Figures 1A, C). The expression of PTGS2,
GPX4 andGSS was rescued by Propranolol (Figures 1F–H). In fact,
the increased H2S levels upon Propranolol exposure (Figure 1J),
indicated that the antioxidant Propranolol property might beA
B C
FIGURE 4 | Erastin (Era) and Propranolol (Prop) do not affect the differentiation route of monocytes into ECs. (A) Neither Era and/or Prop affect the expression of
vWF, even when co-exposed with a short H2O2 stimulation (positive control of the differentiation pattern of monocytes), indicating that Era and/or Prop have no
impact in the differentiation process of monocytes-derived cells into ECs. Era and/or Prop exposure before the short H2O2 stimulation does not influence the
intracellular ROS (DCF-DA; B) and lipid peroxide (11C-Bodipy; C) levels. In (B, C) data are normalized to the control condition and represented as mean ± SD.
*p<0.5, **p<0.01, ***p<0.001, ****p<0.0001.May 2021 | Volume 11 | Article 656229





FIGURE 5 | SeChry@PUREG4 plus Propranolol (Prop) increases cancer cell death through the generation of oxidative stress, while in ECs Prop acts as an
antioxidant, reverting ROS levels induced by SeChry@PUREG4. (A) SeChry@PUREG4 (160 µM and 200 µM) exposure promotes cancer cell death (MDA-
MB-231), being this effect boosted by Prop. (B) ECs (HUVECs) are more resistant to SeChry@PUREG4 -induced cell death, even under Prop exposure.
(C–F) Contrarily to HUVECs, in MDA-MB-231 Prop alone increases (C, D) intracellular ROS (DCF-DA) and (E, F) lipid peroxide (11C-Bodipy) levels and it
does not revert the generation of ROS-induced lipid peroxidation induced by SeChry@PUREG4. (G) SeChry@PUREG4 does not impact the generation of
VE-Cad intercellular junctional gaps. The panel shows representative images (scale: 10 µm) of VE-Cadherin (green) intercellular junctional gaps (arrows). In
graphs the dashed line represents the control condition. All data are normalized to the control condition and represented as mean ± SD. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001.Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 65622911
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oxidative stress by directly scavenging ROS (48, 71).
Considering that the generation of a pro-oxidative
microenvironment is implicated in the promotion of the
angiogenic switch and further angiogenesis (6, 7), we
unraveled, for the first time, the role of the ferroptosis-like
mechanism in ECs activation. We showed that the ferroptosis-
like mechanism induces ECs hyperactivation, by increasing cell
proliferation and migration (Figures 2A, B) and also promoting
the formation of vessel-like structures (Figure 2C), mimicking
the in vivo capacity of ECs to form blood vessels. Interestingly,
Erastin stimulates the formation of vessel-like structures at the
same range of H2O2 (ROS) (Figure 2C), supporting the
involvement of the ferroptosis- l ike mechanism on
angiogenic processes.
Propranolol acts as an inhibitor of angiogenesis and it was
recently described to suppress proliferation, migration and tube
formation of hemangioma cells through the HIF-1a-VEGF-A
axis (72, 73) and to decrease the expression of angiogenic growth
factors, as VEGF and FGF (20). However, the precise cellular
mechanism underlying blood vessels disruption and
angiogenesis impairment is still unknown. In this study, we
observed that Propranolol, besides its anti-angiogenic effect
under basal culture conditions, is able to abrogate the
stimulation of ECs activation induced by Erastin and to
disrupt already established vessel-like structures (Figures 2A–
D), suggesting that the Propranolol anti-angiogenic effect is
related, at least in part, to the abrogation of the ferroptosis-
like mechanism.
The cancer-associated vasculature is characterized by an
increased permeability and interstitial fluid pressure due to the
disruption of ECs junctions, which reveals to be pivotal in cancer
cell adhesion, intravasion and metastasis (74, 75). The increased
VEGF levels, in the tumor microenvironment, promote VE-Cad
adherens junction phosphorylation and internalization in ECs,
leading to an impaired adhesiveness and non-functional vessels
(74, 76). Besides the role of the ferroptosis-like mechanism on
ECs activation, Erastin exposure promotes the formation of VE-
Cad intercellular junctional gaps (Figures 3A, B), which results
in the generation of a leakier ECs structure. This is accompanied
by an increase in ICAM adhesion molecule expression (Figures
3C, D), a crucial protein for cancer cell and ECs interaction
during the metastatic cascade (51–53). Increased ICAM
expression (Figures 3C, D) promotes cancer cell adhesion to
ECs and transendothelial migration (Figures 3F, G). Our results
support that Propranolol contributes to vessel stabilization and
putatively disturbs metastasis, since Propranolol did not alter
VE-Cad intercellular junctional gaps (Figures 3A, B), ICAM
expression and further cancer cell: ECs adhesion (Figure 3F) and
transendothelial cancer cell migration (Figure 3G). Accordingly,
Propranolol reverted the pro-metastatic ECs phenotype induced
by Erastin, by decreasing VE-Cad intercellular junctional gaps
(Figures 3A, B) and ICAM expression (Figure 3C); and by
disturbing cancer cell adhesion to ECs and transendothelial
cancer cell migration (Figures 3F, G). Therefore, the effect of
the ferroptosis-like mechanism, at a non-lethal level, mimics theFrontiers in Oncology | www.frontiersin.org 12pathophysiological angiogenic process in cancer, characterized
by an ECs hyperactivation that leads to the formation of a leakier
vascular network (74, 75, 77, 78). On the other hand, Propranolol
administration blocks the angiogenic switch, decelerating
angiogenesis and further tumor growth, while preventing the
generation of a leakier vasculature, decreasing metastasis and
putatively increasing the delivery of cytotoxic drugs to the
cancer cells.
Recently our group showed that monocytes act as endothelial
progenitor cells that differentiate into ECs upon oxidative stress
and are capable of incorporating into the tumor neo-vasculature,
contributing to cancer progression (35). In this context, we
explored if the pro-angiogenic stimuli pushing monocytes
towards ECs differentiation, also benefited from a ferroptosis-
like mechanism. In fact, we observed that neither Erastin nor
Propranolol interfered with monocytes differentiation into ECs
(Figure 4).
In cancer cells, selenium compounds interfere with the
selenium uptake, selenocysteine biosynthesis and the
production of selenoproteins, such as GPX4, consequently
abrogating cell protection against ferroptosis (79). Moreover,
selenium compounds display antioxidant or pro-oxidant
properties, depending on their concentrations (80, 81); and
they can be used as cytotoxic compounds showing anti-cancer
properties and overcoming cisplatin resistance and multiple drug
resistance (36, 38, 82, 83).
Considering the dual effect of these compounds and the
antioxidant role of Propranolol in ECs, we explored if a
combination of Propranolol with SeChry encapsulated in
PUREG4 nanoparticles (SeChry@PUREG4) could be used as a
strategy to simultaneously induce cancer cell death and stabilize
ECs, resembling tumor vessels. Interestingly, in breast cancer cells
(MDA-MB-231), Propranolol alone increased cell death by 2-fold
(Figure 5A), demonstrating that, besides its role in preventing ECs
hyperactivation, Propranolol could also promote cancer cells
death. Moreover, MDA-MB-231 were more sensitive to
SeChry@PUREG4 than HUVECs, showing higher cell death
levels upon exposure with or without Propranolol (Figures 5A,
B). These results reinforce the anti-tumoral SeChry@PUREG4
effect on ovarian cancer cells, recently described by us (38), and
confirmed the differential effect of Propranolol on cancer cells and
ECs. Interestingly, SeChry@PUREG4 exposure induced ferroptosis
in cancer cells, as it increased the generation of intracellular ROS
and the accumulation of lipid peroxides (Figures 5C, E), which
ultimately promote cancer cell death (Figure 5A). Contrarily to
the observations in HUVECs, in MDA-MB-231, Propranolol did
not display antioxidant features, since the levels of ROS and ROS-
induced lipid peroxides increased upon Propranolol exposure
(Figures 5C, E). In HUVECs, SeChry@PUREG4 had no effect
on the generation of lipid peroxides (Figure 5F) and did not affect
the formation of VE-Cad junctional gaps (Figure 5G), suggesting
that SeChry@PUREG4 does not compromise vessels stability.
Together, these results demonstrate that SeChry@PUREG4 plus
Propranolol administration is a promising strategy for cancer
treatment, since this combination is able to induce cancer cell
death through ferroptosis, while avoiding the formation of aMay 2021 | Volume 11 | Article 656229
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intravasation and metastasis.CONCLUSION
The ferroptosis-like mechanism, mediated by Erastin, through GSH
depletion and ROS-induced lipid peroxide generation is implicated
in the regulation of some pathophysiological ECs features,
promoting ECs hyperactivation, leakiness and cancer cell
migration. Propranolol scavenging activity mediated by H2S
impairs the generation of oxidative stress, reverting the ECs
phenotype observed under Erastin exposure. Additionally, despite
the effects of the ferroptosis-like mechanism on ECs activation, it
did not affect the differentiation process of monocytes into ECs.
Moreover, in this paper we disclose the potential use of
SeChry@PUREG4, a selenium-containing nanoformulation, in
combination with Propranolol, as a good strategy for cancer
treatment. The combination of SeChry@PUREG4 with
Propranolol induces cancer cell death mediated by pro-oxidant
features, while in ECs it prevents the formation of a leakier
vasculature (Figure 6), pivotal in cancer cell intravasation
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FIGURE 6 | Taking advantage of the differential oxidative stress response of cancer cells and endothelial cells (ECs). (A) A pro-angiogenic ferroptosis-like
mechanism, through the generation of ROS, accumulation of lipid peroxides and glutathione (GSH) depletion, is implicated in the promotion of ECs hyperactivation,
vessels leakiness and cancer cell adhesion and intravasation. (B) Propranolol (Prop) ROS scavenging activity is anti-angiogenic, impairing ECs activation underlined
by the ferroptosis-like mechanism. (C) The combination of SeChry@PUREG4 nanoparticles and Prop was unraveled as a potential cancer therapy. SeChry@PUREG4
induces cancer cell death mediated by pro-oxidative features, while Prop stabilizes ECs and prevents the formation of a leakier vasculature, avoiding metastasis.
Prop enhances the pro-oxidative features of Sechry@PUREG4 effect.May 2021 | Volume 11 | Article 656229
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Supplementary Figure 1 | xCT is expressed in endothelial cells (HUVECs)
and in comparison to cancer cells, are more sensitive to the generationFrontiers in Oncology | www.frontiersin.org 14of lipid peroxides induced by Erastin (Era). (A) HUVECs expresses xCT
(green) mainly in mitochondria (TOM20, red), and its expression is not
affected by Era and/or Propranolol (Prop), for 16 h (scale: 20mm). (B) HUVECs
are more sensitive to the generation of Era-induced lipid peroxides
than cancer cells (MDA-MB-231). Two Era concentrations were tested
(1,5mM and 5 mM) during different time points (1, 6 and 16h). In graphs the
dashed line represents the control condition. All data are normalized to the
control condition and represented as mean ± SD. *p<0.05, **p<0.01,
***p<0.001.REFERENCES
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